Join Growin Stock Community!

Adc therapeutics s.a.ADCT.US Overview

US StockHealthcare
(No presentation for ADCT)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ADCT AI Insights

ADCT Overall Performance

ADCT AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ADCT Recent Performance

-0.61%

Adc therapeutics s.a.

0.05%

Avg of Sector

-0.31%

S&P500

ADCT PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ADCT Key Information

ADCT Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ADCT Profile

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Price of ADCT

ADCT FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ADCT Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.75
PB Ratio
2.58
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
92.73%
Net Margin
-221.97%
Revenue Growth (YoY)
6.35%
Profit Growth (YoY)
5.85%
3-Year Revenue Growth
-40.07%
3-Year Profit Growth
-41.24%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.35
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.75
PB Ratio
2.58
Price-to-FCF
-
Gross Margin
92.73%
Net Margin
-221.97%
Revenue Growth (YoY)
6.35%
Profit Growth (YoY)
5.85%
3-Year Revenue Growth
-40.07%
3-Year Profit Growth
-41.24%

  • When is ADCT's latest earnings report released?

    The most recent financial report for Adc therapeutics s.a. (ADCT) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ADCT's short-term business performance and financial health. For the latest updates on ADCT's earnings releases, visit this page regularly.

  • What is the operating profit of ADCT?

    According to the latest financial report, Adc therapeutics s.a. (ADCT) reported an Operating Profit of -30.97M with an Operating Margin of -188.52% this period, representing a growth of 12.92% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ADCT's revenue growth?

    In the latest financial report, Adc therapeutics s.a. (ADCT) announced revenue of 16.43M, with a Year-Over-Year growth rate of -11.03%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ADCT have?

    At the end of the period, Adc therapeutics s.a. (ADCT) held Total Cash and Cash Equivalents of 234.74M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ADCT go with three margins increasing?

    In the latest report, Adc therapeutics s.a. (ADCT) did not achieve the “three margins increasing” benchmark, with a gross margin of 92.7%%, operating margin of -188.52%%, and net margin of -249.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ADCT's profit trajectory and future growth potential.

  • Is ADCT's EPS continuing to grow?

    According to the past four quarterly reports, Adc therapeutics s.a. (ADCT)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ADCT?

    Adc therapeutics s.a. (ADCT)'s Free Cash Flow (FCF) for the period is -29.63M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 17.3% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ADCT?

    The latest valuation data shows Adc therapeutics s.a. (ADCT) has a Price-To-Earnings (PE) ratio of -3.12 and a Price/Earnings-To-Growth (PEG) ratio of 0.08. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.